Lumosa to launch the Phase 2 Study for its LT3001

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke

LT3001 patent granted in Japan and Mexico

Lumosa Therapeutics (Lumosa; code:6535.TWO), a new drug development company in Taiwan, announces that the compound patent of its LT3001, a new drug currently under development for the treatment of acute ischemic stroke (AIS), has been granted by the Japan Patent Office and Mexican Institute of Industrial Property. These are additional patents issued in major markets after the issuance of the United States and China patents. Lumosa’s LT3001 compound patent has been granted in 8 countries so far, including China, the US, Australia, Russia, Taiwan, Indonesia, Japan and Mexico. A total of ten patent applications in other jurisdictions are under examination. 

Formulation patent for Naldebain approved

New U.S. Patent Granted to Lumosa for Naldebain(R), a Long-acting Analgesic for Moderate to Severe Post-Operative Pain

Lumosa partner submitted clinical trial application for LT1001 in China

Lumosa Therapeutics Co., Ltd. (6535. TWO) (“Lumosa”) today announced that its partner, Syntano Technology Venture (“Syntano”), a subsidiary of the Haike group, has submitted Clinical Trial Application (CTA) to the China National Drug Administration (CNDA) for Lumosa’s long-acting analgesic injection, LT1001 (the product name used in Taiwan: Naldebain®) as a Class 5.1 New Drug. Lumosa will receive milestone payment correspondingly. Clinical trials for Class 5.1 (Imported New Drugs) require fewer subjects for confirmatory purpose, which would shorten the registration process for LT1001 to be launched in China.

Shareholders approved the merger of Lumosa and TPG Bio

Shareholders of Lumosa Therapeutics Co., Ltd. (6535. TPEx) (“Lumosa”) approved its merger with TPG Biologics, Inc. (6521. TPEx) (“TPG”) today. One TPG common share will be exchanged for 0.775 Lumosa common share on a one-time issuance basis; resulting in NTD1.16 billion (approximately USD 38 Million equivalent) capital for the post-merger company. The name of the post-merger company will remain “Lumosa Therapeutics Co., Ltd.”. The completion of the merger is tentatively targeted for October 31, 2018 pending government’s regulatory approval.  Shareholders also approved a fundraising plan through private placement, and authorized the board to proceed with the issuance of common shares under a cap of 75,000,000 shares at a face value of NTD10 per share. The final total amount raised will be determined by the actual issuance price and the number of shares issued.

Lumosa BOD approved TPG Biologics acquisition

(June 8, 2018. Taipei) Lumosa Therapeutics Co., Ltd. (6535. TWO) (“Lumosa”, a TpEx listed company) and TPG Biologics, Inc.(6521. TWO) (“TPG”, listed on the Emerging Stock Market of TPEx) held respective board meeting and approved a merger proposal between Lumosa and TPG.  The merger is expected to integrate R&D resources of the two companies, expand the product portfolio, accelerate new drug development, and enhance overall operation performance. The name of the post-merger company will remain “Lumosa Therapeutics Co., Ltd.”.